Loading company…
Palma-based clinical-stage biopharmaceutical company developing treatments for vascular calcification disorders.
Sanifit Therapeutics, S.A. is developing SNF472, a small molecule inhibitor of hydroxyapatite crystallization for calciphylaxis in dialysis patients, which was in phase 3 clinical development as of December 2021. Based in Palma de Mallorca, Spain, and founded in 2007 by Joan Perello, who is CEO, the company raised EUR 17 million in venture debt in June 2019 and has raised USD 128.31 million in total. It is listed at the Series D stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in